{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:01:34Z","timestamp":1790787694491,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100020643","name":"Medical Research Centre","doi-asserted-by":"publisher","award":["MR\/R502145\/1"],"award-info":[{"award-number":["MR\/R502145\/1"]}],"id":[{"id":"10.13039\/501100020643","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sequential B cell-targeted immunotherapy with BAFF antagonism (belimumab) and B cell depletion (rituximab) may enhance B cell targeting in ANCA-associated vasculitis (AAV) through several mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Study design: COMBIVAS is a randomised, double-blind, placebo-controlled trial designed to assess the mechanistic effects of sequential therapy of belimumab and rituximab in patients with active PR3 AAV. The recruitment target is 30 patients who meet the criteria for inclusion in the per-protocol analysis. Thirty-six participants have been randomised to one of the two treatment groups in a 1:1 ratio: either rituximab plus belimumab or rituximab plus placebo (both groups with the same tapering corticosteroid regimen), and recruitment is now closed (final patient enrolled April 2021). For each patient, the trial will last for 2\u00a0years comprising a 12-month treatment period followed by a 12-month follow-up period.<\/jats:p>\n                    <jats:p>Participants: Participants have been recruited from five of seven UK trial sites. Eligibility criteria were age\u2009\u2265\u200918\u00a0years and a diagnosis of AAV with active disease (newly diagnosed or relapsing disease), along with a concurrent positive test for PR3 ANCA by ELISA.<\/jats:p>\n                    <jats:p>Interventions: Rituximab 1000\u00a0mg was administered by intravenous infusions on day 8 and day 22. Weekly subcutaneous injections of 200\u00a0mg belimumab or placebo were initiated a week before rituximab on day 1 and then weekly through to week 51. All participants received a relatively low prednisolone (20\u00a0mg\/day) starting dose from day 1 followed by a protocol-specified corticosteroid taper aiming for complete cessation by 3\u00a0months.<\/jats:p>\n                    <jats:p>Outcomes: The primary endpoint of this study is time to PR3 ANCA negativity. Key secondary outcomes include change from baseline in na\u00efve, transitional, memory, plasmablast B cell subsets (by flow cytometry) in the blood at months 3, 12, 18 and 24; time to clinical remission; time to relapse; and incidence of serious adverse events. Exploratory biomarker assessments include assessment of B cell receptor clonality, B cell and T cell functional assays, whole blood transcriptomic analysis and urinary lymphocyte and proteomic analysis. Inguinal lymph node and nasal mucosal biopsies have been performed on a subgroup of patients at baseline and month 3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This experimental medicine study provides a unique opportunity to gain detailed insights into the immunological mechanisms of belimumab-rituximab sequential therapy across multiple body compartments in the setting of AAV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov NCT03967925. Registered on May 30, 2019.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-023-07218-y","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T16:24:42Z","timestamp":1679847882000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol"],"prefix":"10.1186","volume":"24","author":[{"given":"Mark E.","family":"McClure","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seerapani","family":"Gopaluni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Wason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Van Maurik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline C.O.","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles D.","family":"Pusey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinta","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Mynard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel B.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf the COMBIVAS investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"key":"7218_CR1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221\u201332.","journal-title":"N Engl J Med"},{"key":"7218_CR2","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1213277","volume":"369","author":"U Specks","year":"2013","unstructured":"Specks U, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013;369:417\u201327.","journal-title":"N Engl J Med"},{"key":"7218_CR3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1136\/ard.2011.153601","volume":"71","author":"JU Holle","year":"2012","unstructured":"Holle JU, et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener\u2019s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis. 2012;71:327\u201333.","journal-title":"Ann Rheum Dis"},{"key":"7218_CR4","doi-asserted-by":"publisher","first-page":"c339","DOI":"10.1159\/000323393","volume":"118","author":"M Nagai","year":"2011","unstructured":"Nagai M, et al. Serum levels of BAFF and APRIL in myeloperoxidase anti-Neutrophil cytoplasmic autoantibody-associated renal vasculitis: association with disease activity. Nephron Clin Pract. 2011;118:c339\u201345.","journal-title":"Nephron Clin Pract"},{"key":"7218_CR5","first-page":"62","volume":"28","author":"C Schneeweis","year":"2010","unstructured":"Schneeweis C, et al. Increased levels of BLyS and sVCAM-1 in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV). Clin Exp Rheumatol. 2010;28:62\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"7218_CR6","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nri844","volume":"2","author":"F Mackay","year":"2002","unstructured":"Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol. 2002;2:465\u201375.","journal-title":"Nat Rev Immunol"},{"key":"7218_CR7","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918\u201330.","journal-title":"Arthritis Rheum"},{"key":"7218_CR8","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721\u201331.","journal-title":"Lancet"},{"key":"7218_CR9","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/art.40802","volume":"71","author":"D Jayne","year":"2019","unstructured":"Jayne D, et al. Efficacy and safety of belimumab and azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled study. Arthritis Rheumatol. 2019;71:952\u201363.","journal-title":"Arthritis Rheumatol"},{"key":"7218_CR10","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/art.34400","volume":"64","author":"W Stohl","year":"2012","unstructured":"Stohl W, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64:2328\u201337.","journal-title":"Arthritis Rheum"},{"key":"7218_CR11","doi-asserted-by":"crossref","unstructured":"Arends E, Ziei M, Tipton C, Teng O. Belimumab add-on therapy mobilizes memory B cells into circulation of SLE patients. Abtrast number M0257. ERA-EDTA Congr. Annals of the Rheumatic Diseases. 2021;80 (Suppl 1):585.1\u201385.","DOI":"10.1136\/annrheumdis-2021-eular.248"},{"key":"7218_CR12","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/art.38074","volume":"65","author":"LM Carter","year":"2013","unstructured":"Carter LM, Isenberg DA, Ehrenstein MR. Elevated serum BAFF levels are associated with rising anti\u2013double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. ARTHRITIS Rheum. 2013;65:2672\u20139.","journal-title":"ARTHRITIS Rheum"},{"key":"7218_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1\u201311.","journal-title":"Arthritis Rheum"},{"key":"7218_CR14","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5","volume":"44","author":"JH Stone","year":"2001","unstructured":"Stone JH, et al. A disease-specific activity index for Wegener\u2019s granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum. 2001;44:912\u201320.","journal-title":"Arthritis Rheum."},{"key":"7218_CR15","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1681\/ASN.2014090903","volume":"26","author":"M Hilhorst","year":"2015","unstructured":"Hilhorst M, van Paassen P, Tervaert JWC, Limburg Renal Registry. Proteinase 3-ANCA vasculitis versus myeloperoxidase-ANCA vasculitis. J Am Soc Nephrol. 2015;26:2314\u201327.","journal-title":"J Am Soc. Nephrol."},{"key":"7218_CR16","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1056\/NEJMoa1108735","volume":"367","author":"PA Lyons","year":"2012","unstructured":"Lyons PA, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367:214\u201323.","journal-title":"N Engl J Med"},{"key":"7218_CR17","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1002\/art.24637","volume":"60","author":"RB Jones","year":"2009","unstructured":"Jones RB, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2009;60:2156\u201368.","journal-title":"Arthritis Rheum"},{"key":"7218_CR18","volume-title":"Clinical commissioning policy: rituximab for the treatment of ANCA-associated vasculitis in adults reference: NHS England A13\/P\/a","author":"NHS England","year":"2015","unstructured":"NHS England. Clinical commissioning policy: rituximab for the treatment of ANCA-associated vasculitis in adults reference: NHS England A13\/P\/a. 2015."},{"issue":"5","key":"7218_CR19","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/art.40049","volume":"69","author":"W Stohl","year":"2017","unstructured":"Stohl W, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two\u2013week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2017;69(5):1016\u201327.","journal-title":"Arthritis Rheumatol."},{"key":"7218_CR20","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1136\/annrheumdis-2022-eular.1820","volume":"81","author":"E Arends","year":"2022","unstructured":"Arends E, Zlei M, Tipton C. POS0185 belimumab disrupts memory B-cell trafficking in patients with systemic lupus erythematosus. Ann Rheum Dis. 2022;81:324\u20135.","journal-title":"Ann Rheum Dis"},{"key":"7218_CR21","first-page":"260","volume":"58","author":"RJ Pepper","year":"2018","unstructured":"Pepper RJ, et al. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody\u2013associated vasculitis. Rheumatol. 2018;58:260\u20138.","journal-title":"Rheumatol"},{"key":"7218_CR22","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne DRW, Merkel PA, Schall TJ, Bekker P. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384:599\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa2023386.","journal-title":"N Engl J Med"},{"key":"7218_CR23","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrrheum.2014.103","volume":"10","author":"JC Jennette","year":"2014","unstructured":"Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol. 2014;10:463\u201373.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"7218_CR24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/RHU.0000000000001030","volume":"25","author":"ME McClure","year":"2019","unstructured":"McClure ME, et al. Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis. J Clin Rheumatol. 2019;25(5):217\u201323.","journal-title":"J Clin Rheumatol."},{"key":"7218_CR25","doi-asserted-by":"publisher","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","volume":"116","author":"GS Hoffman","year":"1992","unstructured":"Hoffman GS, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116:488\u201398.","journal-title":"Ann Intern Med"},{"key":"7218_CR26","doi-asserted-by":"publisher","first-page":"826","DOI":"10.4161\/mabs.26008","volume":"5","author":"J Golay","year":"2013","unstructured":"Golay J, et al. Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. mAbs. 2013;5:826\u201337.","journal-title":"mAbs"},{"issue":"Supplement_2","key":"7218_CR27","doi-asserted-by":"publisher","first-page":"057","DOI":"10.1093\/rheumatology\/kez057.029","volume":"58","author":"M McClure","year":"2019","unstructured":"McClure M, et al. 030. Tolerability and cell yield from nasal biopsies obtained in the outpatient setting (abstract). Rheumatol. 2019;58(Supplement_2):057\u2013029.","journal-title":"Rheumatol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07218-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07218-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07218-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T11:52:31Z","timestamp":1702122751000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07218-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,11]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7218"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07218-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2138639\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,11]]},"assertion":[{"value":"6 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A favourable ethical opinion was granted by the National Research Ethics Service Committee East of England Cambridge Central reference number: 18\/EE\/0275. Informed consent has been obtained from all participants in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable for protocol design paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The trial is funded through the GSK-MRC EMINENT programme. Belimumab (Benlysta) is marketed by GlaxoSmithKline (GSK). GSK has provided scientific expertise including advice on trial design, analysis and interpretation of the data and review of the manuscripts. MM is the COMBIVAS trial physician and MRC-GSK EMINENT fellow. RJ is the chief investigator for the study. She has received research funding from GSK, previously undertook an academic secondment to GSK 2011\u20132013, currently undertakes consultancy work for Chemocentryx and has an investigator-initiated study collaboration with Roche. DJ has received research grants from Roche\/Genentech, Chemocentryx and Genzyme\/Sanofi. PAL has received research funding from GSK. CP has consulted for Vifor and Alentis. JW has received research funding from Boehringer-Ingelheim and UCB. AvM, RH and CS are current or previous employees of GSK. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"180"}}